PFO Closure: clear and borderline indications and cases where there is no evidence of benefit Michael Mullen Royal Brompton Hospital London.

Slides:



Advertisements
Similar presentations
Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.
Advertisements

PFO CLOSURE JOURNAL REVIEW OF EVIDENCE.  PFO is a remnant of fetal circulation  At autopsy-Identified in 27% of normal patients  Prevalence decline.
PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
Clinical Trial Results. org Tilman B. Drüeke, M.D.; Francesco Locatelli, M.D.; Naomi Clyne, M.D.; Kai-Uwe Eckardt, M.D.; Iain C. Macdougall, M.D.; Dimitrios.
Canadian Cardiovascular Society Antiplatelet Guidelines
The Cochrane Reviews of Acupuncture Doris Hubbs, MD, FACP April 26, 2013.
Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Is low-dose Aspirin use associated with a reduced risk of colorectal cancer ? a QResearch primary care database analysis Prof Richard Logan, Dr Yana Vinogradova,
MIST I & III Studies Andrew J. Dowson Director Headache Services King’s College Hospital London, UK For the MIST investigators.
Stroke Issues & prevention. Agenda  Impact of Stroke –Definitions –Epidemiology –Risk factors  Management of Stroke –Acute management –Primary & Secondary.
1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Carotid Endarterectomy versus Stenting: Where do we stand today? Vascular Conference March 23, 2010.
OVBIAGELE B, DIENER H-C, YUSUF S, ET AL., PROFESS INVESTIGATORS. LEVEL OF SYSTOLIC BLOOD PRESSURE WITHIN THE NORMAL RANGE AND RISK OF RECURRENT STROKE.
DEREK B. COVINGTON, M.D. RESIDENT PHYSICIAN – PGY2 DEPARTMENT OF ANESTHESIOLOGY UNIVERSITY OF MIAMI/JACKSON MEMORIAL HOSPITAL Modification of Individual.
Migraine Intervention with STARFlex Technology (MIST) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Andrew.
Jonathan A. Edlow, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral.
Atrial Fibrillation Warfarin and its newer alternatives
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Consultant Neurologist,
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
PFO Dr Peter Wilmshurst Royal Shrewsbury Hospital Co-workers: Simon Nightingale, Lindsay Morrison, Matthew Pearson, Kevin Walsh, Phil Bryson, John Davis,
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
1 Statin treatment is associated with improved prognosis in patients with AF-related stroke G. Ntaios, V. Papavasileiou, K.Makaritsis, A.Karagiannaki,
SIGN Non-Pharmaceutical Management of Depression in Adults Recommendations.
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Terutroban versus aspirin in Patients with Cerebral Ischaemic Events (PREFORM): a Randomized, Double- blind Parallel-group Trial Daniel Wells Mercer University.
Jim Hoehns, Pharm.D.. Lancet 2013;382: Albers G et al. Chest. 2001; 119 (suppl): 300S. Ischemic stroke 85% Hemorrhagic stroke 15% Other 5% Cryptogenic.
UBC-Case 1 Samuel Yip PhD, MD, FRCPC Western Stroke Day 2012.
Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 FDA Presentation Advair Diskus 500/50 Carol Bosken, MD, ScM, MPH Medical Officer Division of Pulmonary.
* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):
DHHS / FDA / CDRH 1 FDA Summary CardioSEAL® STARFlex™ Septal Occlusion System with Qwik Load NMT Medical P000049/S3.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
C E N T E R F O R C O N G E N I T A L H E A R T D I S E A S E S T U T T G A R T Presenter disclosure information name: Frank Uhlemann In the last 12 month.
Long-Term Comparison of Medical Treatment With Percutaneous Closure of Patent Foramen Ovale for Secondary Prevention of Paradoxical Embolism: A Propensity-Score.
Sifting through the evidence Sarah Fradsham. Types of Evidence Primary Literature Observational studies Case Report Case Series Case Control Study Cohort.
A Review of – Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Ted Williams Pharm D Candidate Monday Lab.
Can patients be too mild, too severe or too old for thrombolysis? Professor Peter Sandercock University of Edinburgh ESC Hamburg 27 th May 2011 Disclosures.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
PFO Closure : a critical overview of recent data Ramesh Daggubati, MD FACC FSCAI Director of Interventional Cardiology East Carolina University Greenville,
Why Should We Treat PFO? SCAI Interventional Cardiology Fellows Course
Practice Parameter: Risk of Recurrent Stroke and Secondary Stroke Prevention in Patients With Interatrial Septal Abnormalities (An Evidence-Based Review)
Cardioembolic Stroke: Diagnosis and Management
Disclosure Statement of Financial Interest
ResultsIntroduction Atrial Fibrillation (AF) affects 1.2% 1 of the population and 10% of those over the age of 75 2 It is the commonest arrhythmia in primary.
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
©2016 American Academy of Neurology. Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
PFO closure: Review of the Trials for Migraine
PFO FDA Considerations for Labeling and Future Trials
David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators
University of Pennsylvania Philadelphia
on behalf of the TARDIS Investigators
Update on PFO Trials Michael S. Kim, MD, FACC, FSCAI
Patent Foramen Ovale Devices and Trials Update: Is the Current Data Sufficient for Approval? CRT 2017 Feb18-21, 2017 Steven L. Goldberg, MD Medical.
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Setareh Omran, MD Vascular Neurology Fellow
Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.
Presenter Disclosure Information
Presentation transcript:

PFO Closure: clear and borderline indications and cases where there is no evidence of benefit Michael Mullen Royal Brompton Hospital London

PFO Closure: clear and borderline indications and cases where there is no evidence of benefit Research GrantsNMT medical Edwards Life Science Corevalve Inc Medical Advisory BoardSutura Inc Cardio-optics ConsultancySutura Inc I have a PFO

Stroke Migraine DCI Cyanosis Dementia COPD OSA

Prevalence of PFO Stroke/TIA Migraine DCI OSA COPD Dementia CFS % with PFO

PFO Closure: clear and borderline indications and cases where there is no evidence of benefit “The only good PFO is a closed PFO” …..Dr Bernard Meier “There is no clear indication for PFO closure” …..Most neurologists

Stroke

Webster MW; Lancet 1988Webster MW; Lancet 1988 –40 stroke patients < 40 yrs old + matched controls –Contrast echo +ve 50% of patients 15% controls Lechat P; NEJM 1988Lechat P; NEJM 1988 –60 stroke patients < 55 yrs old controls Patent Foramen Ovale Cryptogenic stroke

AllOther cause CSRF Lechat P; NEJM 1988 % with PFO

Patent Foramen Ovale Meta-analysis of risk of stroke PFO All PFO +ASA ASA PFO Age<55 ASA PFO Age>55 ASA PFO CS vs IC PFO +ASA ASA Overell Neurology 2000

Patent Foramen Ovale CS recurrence rate –Mas JL et al; NEJM 2001 –581 patients with CS followed for over 4 yrs –All patients received Aspirin 300mg/day –Recurrence rates PFO 2.3% (95%CI: 0.3 to 4.3)PFO 2.3% (95%CI: 0.3 to 4.3) PFO+ASA15.2% (95%CI: 1.8 to 28.6)PFO+ASA15.2% (95%CI: 1.8 to 28.6) No PFO 4.2% (95%CI: 1.8 to 6.6)No PFO 4.2% (95%CI: 1.8 to 6.6)

Device Closure of PFO Windecker; JACC 2004

Device Closure of PFO Device closure vs medical therapy Khairy; Heart 2004

Device Closure of PFO RCTs in Stroke RESPECT PFO (USA)RESPECT PFO (USA) –500 patients –Amplatzer PFO vs standard medical therapy –Equivalence trial –Recruitment nearing completion PC trial (Europe)PC trial (Europe) –410 patients –Amplatzer PFO device vs medical therapy –Recruitment nearing completion Closure I trial (USA)Closure I trial (USA) –Starflex vs best medical therapy in CS with PFO –800 patients powered to test superiority over medical treatment –Recruitment completed Q –Results Q4 2009???

Device Closure of PFO Indications for closure ClearClear –Proven cryptogenic stroke –Pathological PFO –Young age –Multiple events or recurrence on treatment BorderlineBorderline –First stroke –TIA –Small PFO –Older age with other RFs Little evidence of benefitLittle evidence of benefit –Primary prevention of stroke –Trivial shunt –Other clear cause

Stroke DCI

Decompression illness and PFO First reported by Wilmshurst in BMJ 1986 postulated link between PFO and DCIFirst reported by Wilmshurst in BMJ 1986 postulated link between PFO and DCI Risk of DCI increased x5 in divers with PFORisk of DCI increased x5 in divers with PFO Increased incidence with size of defectIncreased incidence with size of defect Torti et al Eur H J 2004 No data on benefit of closureNo data on benefit of closure Despite this closure recommended for professional diversDespite this closure recommended for professional divers Social divers have the option of giving up, diving within safe limits or having PFO closureSocial divers have the option of giving up, diving within safe limits or having PFO closure

Stroke Migraine DCI

PFO and migraine Prevalence of migraine increased in patients with PFOPrevalence of migraine increased in patients with PFO Prevalence of PFO increased in patients with migrainePrevalence of PFO increased in patients with migraine PFO and migraine both associated with cryptogenic strokePFO and migraine both associated with cryptogenic stroke Stang Neurology 2005 Shwedt Cephalgia 2006

Effect of PFO Closure on Migraine Observational studies 70% % Reisman % 89 42% Azarbal, % % Reisman % cured 66 39% Post % % Schwerzmann % 62 27% Morandi % 3757% Wilmshurst 2000 % improved or cured (%) migraine No91% % Giardini % 41 24% Kimmelstein % 92 27% Luermans % % Dubiel 2008

Effect of PFO Closure on Migraine prospective studies SSSACtrls Pre Post Stroke 2006 N=77 All patients had migraine PFO closure SS - Previous stroke N=23 SA - No stroke N=27 DCI, TIA, migraine,MI No PFO closure Ctrls - N=27 Follow-up 1 year Composite score of migraine frequency, severity and aura

MIST I Study Protocol Assessment by headache specialist 3 month analysis phase by headache specialist TOE under GA and randomisation Contrast echo 3 month healing phase PFO closure with Starflex Sham procedure

MIST I Study 163/432 (38%) patients had right to left shunts consistent with a moderate or large PFO.163/432 (38%) patients had right to left shunts consistent with a moderate or large PFO. 147 patients were randomised.147 patients were randomised. No difference in the primary endpoint of migraine headache cessation between the implant and sham groups (3/74 versus 3/73 respectively).No difference in the primary endpoint of migraine headache cessation between the implant and sham groups (3/74 versus 3/73 respectively).

MIST I Study What went wrong?What went wrong? Why MIST I results so different from previous observational data?Why MIST I results so different from previous observational data?

MIST I Study RCTs often less positive than observational studiesRCTs often less positive than observational studies –Prospective and contemporaneous measurement of outcomes –Better recording of AEs –inclusion and exclusion criteria bias population so becomes non representative

MIST I Study –MIST I patients were fundamentally different to those in the observational studies Severe, migraine refractory to medical treatmentSevere, migraine refractory to medical treatment IHS guidelines lack precision and may include patients with CDH, depressionIHS guidelines lack precision and may include patients with CDH, depression Patients with other indications for PFO closure excludedPatients with other indications for PFO closure excluded

MIST I Study Too shortToo short Device performanceDevice performance Confounding effects of aspirin and clopidogrelConfounding effects of aspirin and clopidogrel Other shuntsOther shunts Wrong endpointWrong endpoint

Should PFO be closed for migraine Results of MIST study do not support routine PFO closure for migraine alone –Results of MIST study do not support routine PFO closure for migraine alone – however observational data still highly suggestive of link and in selected cases it is justifiedhowever observational data still highly suggestive of link and in selected cases it is justified

PFO and migraine Case History 13 yr old girl13 yr old girl Frequent incapacitating vertigoFrequent incapacitating vertigo HeadacheHeadache Occ visual auraOcc visual aura Well between attacksWell between attacks Normal neurological examinationNormal neurological examination Normal MRI and EEGNormal MRI and EEG Missing significant amount of schoolMissing significant amount of school Large resting shunt on echoLarge resting shunt on echo

PFO and migraine Case History Neurological opinionNeurological opinion Met with parents and patient on 2 occasionsMet with parents and patient on 2 occasions Explained potential for benefit (~50%) and potential for complication (death <1:1000, embolization 1:200, tamponade 1:500, stroke 1:500, transient AF 1:10)Explained potential for benefit (~50%) and potential for complication (death <1:1000, embolization 1:200, tamponade 1:500, stroke 1:500, transient AF 1:10) Catheterisation under GA July 2007Catheterisation under GA July 2007 Large PFO – closed with 28 mm BioSTARLarge PFO – closed with 28 mm BioSTAR No complicationsNo complications FU Jan 08FU Jan 08 Almost complete resolution of symptomsAlmost complete resolution of symptoms No loss of schoolNo loss of school

Stroke Migraine DCI Cyanosis

Stroke Migraine DCI Cyanosis Dementia COPD OSA

Orthodeoxyia Platypnoea Postural related hypoxia due to large PFOPostural related hypoxia due to large PFO –Post pneumonectomy –Aortic root dilatation Usually very large PFOUsually very large PFO PFO closure results in immediate improvementPFO closure results in immediate improvement Anecdotal reports and small case series onlyAnecdotal reports and small case series only

Hacievliyagil S et al. Respir Med 2006 PFO closure for respiratory disorders PFO closure for respiratory disorders Anecdotal reports of benefit in selected patientsAnecdotal reports of benefit in selected patients Few small trials ongoingFew small trials ongoing Should not be part of routine practiceShould not be part of routine practice

Indications for PFO closure Benefit Likelihood of causal relationship Size of shunt Risk Size of defect Experience of operator Technological advances

Superstitch

Conclusion Large body of evidence for pathological link between PFO and a range of clinical syndromes where right to left shunt is a plausible mechanismLarge body of evidence for pathological link between PFO and a range of clinical syndromes where right to left shunt is a plausible mechanism Increasing observational data suggests benefit in some patientsIncreasing observational data suggests benefit in some patients Results of RCTs awaitedResults of RCTs awaited In the meantime PFO closure indicated in selected patients with clinical syndrome and ‘pathological’ shunt if they understand and accept the potential for complications and potential for (or lack of) benefitIn the meantime PFO closure indicated in selected patients with clinical syndrome and ‘pathological’ shunt if they understand and accept the potential for complications and potential for (or lack of) benefit